XERIS BIOPHARMA HOLDINGS INC XERS
ASignal's systematic analysis rates XERS as Neutral.
Reflects the latest available analysis · analyzed Nov 10, 2026
The case on XERS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- High revenue growth (44.2%) indicating strong top-line expansion
- Exceptional gross margin (87.38%) suggesting pricing power or low production costs
- Positive free cash flow ($51.11M) despite net losses
- Strong operating cash flow ($73.65M) supporting operational sustainability
- Low beta (0.84) indicating below-market volatility
- RSI at 79.97 indicating overbought conditions
- Negative return on equity (-27.11%) signaling poor capital efficiency
- High forward P/E (59.47x) and EV/EBITDA (50.78x) suggesting elevated valuation
- High debt-to-equity ratio (4.63x) raising financial risk concerns
- Price significantly above upper Bollinger Band (14.42 vs 15.86), indicating potential price extension
See the full verdict on XERS
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes XERS
Most investors never get a second opinion, let alone several. ASignal runs XERS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.